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Two big international initiatives have the
provocative goal to bundle information
and to act as a platform for exchange to
unravel the mysteries of brain function.
Current technical limitations to brain dis-
covery science represent clear-cut entry
points for both initiatives. Generation of
conceptual breakthroughs in brain sci-
ence, however, represents the main chal-
lenge and reason for excitement. For
success, both initiatives will need strong
interactions with individual scientists to
benefit from in-depth knowledge and bio-
logical understanding in their area of
expertise. It will only be through this strat-
egy that large data sets will be meaningful
and that principles for how the brain
works and dysfunctions in disorders can
be extracted.
Insight should emerge from mining
multidimensional data including the
following areas. Diversity: identification
of mechanisms translating molecular into
functional diversity will help to understand
the distinct languages of neuronal sub-
types. Space: binding together knowl-
edge on local circuit and long-range
computationswith neuromodulatory influ-
ence will provide an integral view on brain
function. Time: understanding the tempo-
ral axis of neuronal-cell-type maturation
and plasticity will help unravel selective
neuronal response profiles in disease.
Organism: comparing differences be-
tween brains of one species and across
species will uncover principles of over-
arching conservation and divergence in
circuit modules.A Down Payment on the Brain
Michael D. Ehlers
Neuroscience Research Unit, Pfizer, Inc.
The brain has long been fascinating and
mysterious, but the science of the brain
and nervous system is increasingly critical
for social well being. The economic
burden of neurological and psychiatric ill-
nesses dwarfs other areas of human dis-
ease. Neurodegenerative disease care is
poised to consume vast swaths of health
care budgets around the globe. Depres-
sion remains the single largest cause of
disability, adjusted for life years, in the
U.S. Stroke remains a major killer. Unfor-
tunately, few new therapies for neurosci-
ence diseases have been developed,
and neuroscience research dollars have
lagged.
Now with the advent of the Obama/NIH
BRAIN Initiative and the EU’s Human
Brain Project, there is an opportunity to
accelerate fundamental brain sciences.
The ambitions of both initiatives are
grand, but less clear is whether these
grand ambitions will be supported by suf-
ficient funds. In the case of the BRAIN
Initiative, $100 million (perhaps a bit
more) will be targeted to brain science
across multiple federal agencies. This
compares to the $500-700 million plus
required to conduct a single phase 3 clin-
ical development program for one experi-
mental drug in Alzheimer’s disease, or
the $1.5 trillion or so in annual costs of
brain disorders in the U.S. and E.U. com-
bined. It is reassuring that policy leaders
are recognizing the need and the opportu-
nity. Beyond this initial down payment,
now is the time to invest and resource
accordingly.Cell 155Big Science Needs New Concepts
Yves Fre´gnac
CNRS, Unit of Neuroscience, Information and
Complexity
As a member of the Human Brain Project
(HBP), I am divided between two attitudes.
One isoptimistic: thesetwocomplementary
initiativeswill yieldnonincrementalprogress
in medicine and systems neuroscience.
HBP is centered on neuroinformatics and
virtual (simulation-driven) medicine; The
NIH initiative will provide the essential
measures for constraining models.
The other is a thread of doubt: multi-
omic research will create gigantic data
sets, and an exhaustive multiscale
description of observations. We will then
face the challenge of handling the
complexity of the contextual and infinitely
dynamic integration of processes that are
the essence of living behavior.
Both international projects engage sci-
entific policies with diverse objectives
and investments in basic sciences. My
hope is that the community will have the
wisdom to define new standards of mac-
romanagement and construct scientific
strategies that bind together the two ini-
tiatives. To understand and simulate the
autonomy and the power of abstraction
of human cognition, we need to integrate
knowledge from the wealth of structural
and functional data and go beyond
bottom-up functional genomics.
We are not yet well armed for this: cur-
rent interpretations of brain function are
governed by principles from the past cen-
turies, if not from Aristotelian times. Big
Science is nowadays driven by technical
prowess, but there is no definitive con-
ceptual model of the Brain. Above all, we
need new concepts to understand the




The U.S. and European brain initiatives
reflect growing societal concern about
mental illness and attempts to spur solu-
tions through directed investment. The
focus on technology development, rather
than on mental illness per se is perhaps a
surprising consensus but a wise one. His-
torically, attempts to promote cures to
complex diseases have yielded unmet
goals, notably in the ‘‘war on cancer.’’
But well-defined ‘‘engineering’’ projects
have succeeded and leveraged further
discovery, as with the Human Genome
Project. While neuroscience has garnered
much fundamental knowledge, we face
more complex problems than anything
tackled scientifically before. We are still
in an age of exploration not exploitation.
To cure complex brain malfunctions, we
will need to leverage still more discov-
eries. And these will likely be facilitated
by new technologies to monitor and
model brain function, as promised by the
brain initiatives. But I would wager that
instrumentation and simulation may not
be enough. Solving the brain will also
require truly new forms of scientific
collaboration and collective discovery.
Social media (Facebook, Twitter, etc.)
have profoundly impacted social lives
and geopolitical events but have yet to
transform science. In the brain initiatives,
one can see the seeds of such a ‘‘social
scientific revolution’’. But a concerted
effort to foster better social technologies
for science may be in order. The much-
anticipated neuroscientific ‘‘spring’’ might
actually depend on it.266 Cell 155, October 10, 2013 ª2013 ElseviThe Other Half
Jennifer Raymond
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I teach a graduate seminar where we train
the next generation of neuroscientists to
design experiments to uncover principles
of brain function. For most of the course,
students design experiments constrained
by existing technologies. But at the end of
the course, we encourage them to dream
big and imagine what they would do if
they had the ability to measure anything
theywanted about the brain—everymole-
cule, structural detail, and electrical signal
of every neuron. As students engage in
this exercise, they quickly realize that bet-
ter experimental tools and more data
cannot replace the need for thoughtfully
designed experiments to address specific
questions. Supporters of the Obama/NIH
and European brain initiatives must like-
wise recognize that the tools and data-
bases they are promising are only half of
the solution. We also need scientists
who can skillfully apply such tools to spe-
cific questions about how neural circuits
function. Unfortunately, scientists with
this expertise are now struggling to sur-
vive low research-funding levels, and
talented young scientists are seeing this
and rejecting research careers because
they don’t seem like a viable option.
Thus, the success of the ‘‘big data’’ brain
initiatives in accelerating discovery and
cures will depend entirely on whether
they are accompanied by improved sup-
port for investigator-initiated, hypothe-
sis-driven research. Investment in better
hammers will not pay off if the skilled
carpenters go out of business.er Inc.Moving Parkinson’s
Tom Isaacs
The Cure Parkinson’s Trust
Since first being diagnosed with Parkin-
son’s some 20 years ago at the age of
26, my resolve to see improvements in
the treatment of Parkinson’s has become
as all-consuming as the condition itself.
During this time, my initial concern for
my personal well being shifted to dismay
at the misery that Parkinson’s causes
some 6 million people around the world
and the unnecessary barriers which stand
in the way of possible breakthroughs in
treating the condition. I have no doubt
about the potential for scientific advances
to dramatically improve Parkinson’s
treatment, but the combination of bureau-
cracy, an increasingly risk averse phar-
maceutical industry, and a general dearth
of investment in the sector has meant that
the progress made in Parkinson’s has
been about as dynamic as I am in the
morning without my medication.
For those of us who have Parkinson’s,
there is an urgent need for those in power
to unlock the shackles of neuroscience.
Now is the time to release the vast poten-
tial of progress in scientific understanding
and to allocate resource so that these ad-
vances can make an impact on the actual
lives of those who live with this condition.
My hope is that the current international
investments in brain research will priori-
tize collaborations between government,
industry, and academic scientists that
will enable kinds of breakthroughs in
Parkinson’s that I know we are poised to
make.
